Clinical and demographic features of subjects included in this study. Values are n (%) or mean ± SD unless otherwise specified.
| Feature | Result |
|---|---|
| N | 238 |
| Female | 174 (73) |
| Race/ethnicity | |
| Hispanic | 3 (1.3) |
| White | 204 (86) |
| African American | 30 (13) |
| Mixed | 1 (0.4) |
| Category | |
| Oligoarticular | 114 (48) |
| RF− polyarticular | 37 (16) |
| RF+ polyarticular | 11 (4.6) |
| Psoriatic JIA | 27 (11) |
| Enthesitis-related arthritis | 43 (18) |
| Systemic JIA | 6 (2.5) |
| Age at final MRI | 13.2 ± 4.2 |
| Duration since JIA diagnosis, yrs | 4.0 ± 3.1 |
| Duration since first IACS, yrs | 2.1 ± 1.3 |
| No. IACS | |
| 1 | 114 (48) |
| 2 | 88 (37)* |
| 3 | 30 (13)** |
| ≥ 4 | 6 (2.5) |
| No. IAI | |
| 0 | 183 (77) |
| 1 | 15 (6.3) |
| 2 | 26 (11) |
| 3 | 6 (2.5) |
| ≥ 4 | 8 (3.3) |
| Systemic medications | |
| None | 10 (4.2) |
| cDMARD only | 15 (6.3) |
| bDMARD ± cDMARD | 213 (90) |
| IL-1 or IL-6 antagonist | 6 (2.5) |
| TNFi | 209 (88) |
| ABA | 19 (8.0) |
| RTX | 5 (2.1) |
↵* Of the 88 subjects who had 2 rounds of IACS, treatment was bilateral in 86; 1 subject underwent unilateral injection once and the other received unilateral injections on both occasions.
↵** Of the 26 subjects who had 3 rounds of IACS, 2 had unilateral injections on 2 occasions, and 1 had a unilateral injection on 1 occasion. All IAI injections were bilateral. RF: rheumatoid factor; JIA: juvenile idiopathic arthritis; MRI: magnetic resonance imaging; IACS: intraarticular corticosteroids; IAI: intraarticular infliximab; cDMARD: conventional disease-modifying antirheumatic drug (hydroxychloroquine, leflunomide, methotrexate, mycophenolate mofetil, sulfasalazine); bDMARD: biologic DMARD; IL-1: interleukin 1; TNFi: tumor necrosis factor inhibitors; ABA: abatacept; RTX: rituximab.